GAITHERSBURG, Md., Nov. 13,
2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
global company advancing protein-based vaccines with its Matrix-M™
adjuvant, today announced that it will participate in the Jefferies
London Healthcare Conference.
|
Conference
Details:
|
|
|
|
Fireside
Chat
|
|
|
Date:
|
Wednesday, November 20,
2024
|
|
Time:
|
11:00 – 11:25 a.m.
Greenwich Mean Time
|
|
Location:
|
London, United
Kingdom
|
|
Moderator:
|
Roger Song, MD, CFA,
Equity Analyst
|
|
Novavax
participants:
|
John C. Jacobs,
President and Chief Executive Officer and Additional Management
Team Members
|
|
|
|
Investor
Meetings
|
|
|
Date:
|
Wednesday, November 20,
2024
|
Recordings
A replay of the fireside chat will be
available on the Events & presentations page of the Company's
website at ir.novavax.com for 30 days from the date of the
conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to help protect against serious infectious
diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. The Company's
portfolio includes its COVID-19 vaccine and its pipeline includes
COVID-19-Influenza Combination and stand-alone influenza vaccine
candidates. In addition, Novavax's adjuvant is included in the
University of Oxford and Serum
Institute of India's R21/Matrix-M
malaria vaccine. Please visit novavax.com and
LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
202-709-5563
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-jefferies-london-healthcare-conference-302303166.html
SOURCE Novavax, Inc.